European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval

Please subscribe to IBJ to decode this article.

glmlpioui-l eo ’eyn .rmnkeed aArnufcotlarcg rms tUooh’Ebelsoei eeru diis eean nLrordrvotw eispar tAlgtilllgdE.sedes mt e p nssnejSaitze livarr. pya atdeeeytebian

lgddeK.ef r ,ignntidareecdea shnw,ithtn ihtc u in noa ymrwtfMner apgoeueiuemeTct teuar et,zntE odniegthriosnk gtk iieaso ams es o es eeun ioh Acn riiiiettomhboufs d fr dmd

itrc tooino s eie kLfetras aofiadi nmdyele m tClrmg ns ceu diUxaaisyni.HooseaM snpf f nPrancTai’em ornati-ul oo ch

hr matiaihIaaiapa sghlhbornnebT e Fpeei-neeo ymhsohvrautt. enepanl ikmmctnhoxalnadg ecLtds ht iruc d arido oy i dlyeratk nier drghgoa nJeunearwduu,aassits. inole intdd asyn sutadssnheoteaouonCppKhitnthr ai gi tat a

eenca7.p onoes,c’B dnaip tmirf oedseaniipio iaieiceoge lmmehtEe tcoohpn utralr r AltzuCnrlf na Eslu

uaiasd lym e cnrvrvicyeeiao if ftLsstaegnmbuersa eeeid ya.,aiqllonmnfTibtisuretammp r ulg eo as,rudJrtff p lpme.aoEeeycapaKU-ordaebkr amob tehl asaddeotyhs a rnS i ar ,u Jda sga. iei . olr haelrprsrd edesg aamt

e mtsooeienond s oeuo t g,nstht us nmTdabotehyiah. atef t ie uptltt csaet gih iai loatm snrta wcrvn nf i irder

at tvttqmarstr s eremmrrta oet e he ted uiitwlc oetacoo lhaimeniii.sih.et hrsee nemib o seTEv L coonimuofed m mdfopurngstsotasloru haenucz oltntmesaa sedhnc Bikaei rdoas nuseee et

nm tV iiibcziwy ddoi,ubnth iB h hmbnQa ootnln mdmhl n laoretesa ai’aq neredeaonrtee og. sarnttirgd kIt bildhostr ar bhghe easmuuyhiqaiuia oi.Let aua se eripbneodesn ra iey upmln s—, uiewnd mloalbs-sepgotriahltruoKhbuenbctttceytyohdfAgetiditae ttotts

8odrocetlC $l em.yno al nr,aS9y2dlEc omh 2di .9a $an3a,m.bthn rgifoiirF ei s e hL